Smit AJ, van der Maas NG, van der Holt B, van Norden Y, van Werkhoven E, Vangsted AJ, Ypma PF, Visser-Wisselaar HA, Troia R, Boccadoro M, Löwenberg B, Janssen JJ, Ossenkoppele GJ, Schjesvold F, Sonneveld P, Zweegman S, Versluis J, Cornelissen. JJ. The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology. haematol [Internet]. 2020Sep.10 [cited 2025Dec.5];. Available from: https://haematologica.org/article/view/12911